Clinical trials: Cancer of Nasopharynx
Nasopharyngeal Cancinoma (NPC), Radiation-induced Oral Mucositis
Prevention and Treatment of Radiation-Induced Oral Mucositis in NPC With Houyanqing Oral Liquid
To explore the efficacy of Houyanqing Oral Liquid combined with conventional treatment in preventing and treating radiation-induced oral mucositis, so as to improve the quality of life of nasopharyngeal carcinoma patients…
- Trial name
- NCT07311772
- Testing
- Houyanqing Oral Liquid, Conventional Treatment for Radiation-Induced Oral Mucositis
- Where
- 16 sites in China
- Volunteers
- 386 people
- Sponsor
- Sun Yat-sen University
Surgery, Recurrent Nasopharyngeal Carcinoma
Plasma Radiofrequency Ablation at Low Temperature Versus Electrocautery Block Resection at High Frequency for Localized Recurrent Nasopharyngeal Carcinoma
This study aims at exploring whether plasma radiofrequency ablation at low temperature is associated with better survival outcome in localized recurrent nasopharyngeal carcinoma by conducting a randomized controlled trial of…
- Trial name
- NCT04425265
- Testing
- Plasma radiofrequency ablation, Electrocautery block resection
- Where
- 3 sites in China
- Volunteers
- 500 people
- Sponsor
- Sun Yat-sen University
Nasopharyngeal Carcinoma
The Efficacy of Camrelizumab Plus Stereotactic Body Radiotherapy in R/M NPC
Camrelizumab is an antibody targeting programmed death receptor 1 (PD-1) and its ligand programmed death-ligand 1 (PD- L1) that is designed to boost the immune system. It does this by allowing immune cells to fight the cancer.
- Trial name
- NCT04830267
- Testing
- Camrelizumab, Stereotactic body radiotherapy
- Where
- 3 sites in China
- Volunteers
- 39 people
- Sponsor
- Chongqing University Cancer Hospital
Wilms Tumor, Fibrosarcoma
Study of High-Dose Chemotherapy With Bone Marrow or Stem Cell Transplant for Rare Poor-Prognosis Cancers
The purpose of this study is to determine whether very high dosages of chemotherapy will improve the chance of surviving cancer.
- Conditions
- Wilms Tumor, Fibrosarcoma, Carcinoma, Round Cell, Nasopharyngeal Cancer
- Trial name
- NCT00141765
- Testing
- Myeloablative Chemotherapy, Stem Cell Rescue
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- University of Michigan Rogel Cancer Center
Nasopharyngeal Cancinoma (NPC), Nasopharangeal Cancer
LDRT Combined With Toripalimab and Chemotherapy for Recurrent/Metastatic NPC
This study aims to evaluate the efficacy and safety of LDRT combined with toripalimab and GP chemotherapy in patients with recurrent or metastatic nasopharyngeal carcinoma through a prospective, open-label, single-arm Phase II…
- Trial name
- LIGHT (NCT07325539)
- Testing
- Gemcitabine(GEM), Cisplatin, Toripalimab
- Where
- 2 sites in China
- Volunteers
- 55 people
- Sponsor
- Sun Yat-sen University
Head and Neck Cancer
Irinotecan and Docetaxel in Treating Patients With Metastatic or Locally Recurrent Head and Neck Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more cancer cells.
- Trial name
- NCT00040807
- Testing
- docetaxel, irinotecan hydrochloride
- Where
- 43 sites in United States
- Sponsor
- Eastern Cooperative Oncology Group
Nasopharyngeal Cancer
Weekly Docetaxel Plus Cisplatin as the First-line Therapy for Nasopharyngeal Cancer
The investigators will evaluate weekly docetaxel plus 3-weekly cisplatin regimen as the first-line therapy for recurrent of metastatic nasophayngeal cancer
- Trial name
- NCT01312311
- Testing
- Docetaxel, Cisplatin
- Where
- South Korea
- Volunteers
- 51 people
- Sponsor
- Samsung Medical Center
Nasopharynx Cancer, Radiotherapy
3DV+TPS Applied to Radiotherapy for Nasopharyngeal Carcinoma
Verify that 3DV+TPS is non-inferior compared to existing imported TPS and superior to existing domestic TPS.
- Trial name
- NCT03791944
- Testing
- 3DV+TPS/VARIAN, TPS / VARIAN, 3DV + TPS / Domestic Accelerator
- Where
- China
- Volunteers
- 100 people
- Sponsor
- Xinqiao Hospital of Chongqing
Metastatic Squamous Neck Cancer With Occult Primary Squamous Cell Carcinoma, Recurrent Metastatic Squamous Neck Cancer With Occult Primary
Saracatinib in Treating Patients With Recurrent or Metastatic Head and Neck Cancer
This phase II trial is studying the how well saracatinib works in treating patients with metastatic or recurrent head and neck cancer.
- Conditions
- Metastatic Squamous Neck Cancer With Occult Primary Squamous Cell Carcinoma, Recurrent Metastatic Squamous Neck Cancer With Occult Primary, Recurrent Squamous Cell Carcinoma of the Hypopharynx, Recurrent Squamous Cell Carcinoma of the Larynx
- Trial name
- NCT00513435
- Testing
- saracatinib, laboratory biomarker analysis
- Where
- United States
- Volunteers
- 9 people
- Sponsor
- National Cancer Institute (NCI)
Recurrent Nasopharyngeal Carcinoma
Nimotuzumab for Recurrent Nasopharyngeal Carcinoma
The study assessed the clinical efficacy, and safety of the combination of Nimotuzumab administered concomitantly with intensity modulated radiation therapy(IMRT) in patients with recurrent nasopharyngeal cancer.
- Trial name
- NCT03666221
- Testing
- Nimotuzumab
- Where
- China
- Volunteers
- 67 people
- Sponsor
- Fujian Cancer Hospital
Nasopharyngeal Carcinoma
Intermittent Oral-esophageal Tube in Delayed Dysphagia After Radiotherapy for Nasopharyngeal Carcinoma
This is a prospective multicenter study with patients with delayed dysphagia after radiotherapy for NPC. Patients enrolled are randomly divided equally into the observation group and the control group.
- Trial name
- NCT06248840
- Testing
- Intermittent Oral-esophageal Tube Feeding, nasogastric tube feeding
- Where
- China
- Volunteers
- 56 people
- Sponsor
- Zeng Changhao
Nasopharyngeal Carcinoma
Valproic Acid in the Induction of EBV Lytic Cycle Antigen Expression in Nasopharyngeal Carcinoma
The proposed study will test the safety and efficacy of sodium valproate in the induction of Epstein-Barr virus (EBV) lytic cycle antigen expression in tumor tissue of patients undergoing primary therapy for nasopharyngeal…
- Trial name
- NCT00181220
- Testing
- valproic acid
- Where
- Singapore
- Sponsor
- Johns Hopkins University
Nasopharyngeal Carcinoma
Nedaplatin in Treatment for Nasopharyngeal Carcinoma
To evaluate the efficacy of induction chemotherapy with nedaplatin, docetaxel and 5-Fluorouracil followed by concurrent nedaplatin combined with radical radiotherapy in locally advanced nasopharyngeal carcinoma.
- Trial name
- NCT04834206
- Testing
- Docetaxel, nedaplatin, fluorouracil, IMRT, Nedaplatin
- Where
- China
- Volunteers
- 32 people
- Sponsor
- Affiliated Cancer Hospital & Institute of Guangzhou Medical University
Colorectal Cancer, Head and Neck Cancer
Immunoreactivity to Cetuximab in Cancer Patients
RATIONALE: Studying samples of blood in the laboratory may help doctors predict which patients will develop hypersensitivity to cetuximab.
- Trial name
- NCT00896896
- Testing
- immunologic technique, laboratory biomarker analysis
- Volunteers
- 538 people
- Sponsor
- Vanderbilt-Ingram Cancer Center
Nasopharyngeal Carcinoma
Tislelizumab in Combination With GP or TPC Regimen for the Treatment of Nasopharyngeal Carcinoma With Bone Metastasis.
This is a prospective, open-label phase III clinical trial evaluating the efficacy and safety of the GP（Gemcitabine combined with cisplatin） regimen in combination with Tislelizumab versus the TPC（cisplatin, nab-paclitaxel and…
- Trial name
- NCT06383780
- Testing
- GP combined with Tislelizumab, TPC combined with Tislelizumab
- Where
- China
- Volunteers
- 90 people
- Sponsor
- XIANG YANQUN
Recurrent and Metastatic Nasopharyngeal Carcinoma
Nedaplatin Combined With Gemcitabine in the Treatment of Recurrent and/or Metastatic Nasopharyngeal Carcinoma : a Single Arm and Phase Ⅱ Clinical Trail
The purpose of this single arm,phase Ⅱ clinical trail is to determine the safety and efficacy of nedaplatin combined with gemcitabine in the treatment of recurrent and metastatic nasopharyngeal carcinoma
- Trial name
- NCT02789189
- Testing
- nedaplatin and gemcitabine
- Volunteers
- 60 people
- Sponsor
- Sun Yat-sen University
Nasopharyngeal Carcinoma by AJCC V9 Stage
Risk-Adapted Omission of Level Va Irradiation in Nasopharyngeal Carcinoma
This is a randomized, phase III, prospective, multi-center trial in newly diagnosed nasopharyngeal carcinoma (NPC) patients without distant metastasis.
- Trial name
- NCT07268690
- Testing
- Omission of Level Va Irradiation in Nasopharyngeal Carcinoma
- Where
- China
- Volunteers
- 474 people
- Sponsor
- Fujian Cancer Hospital
Nasopharyngeal Carcinoma ,Xerostomia,Radiotherapy
Xerostomia-optimised IMRT Versus Standard IMRT in NPC
This is a multi-center, non-inferiority, open-label, randomized controlled phase III clinical trial in primary diagnosed nasopharyngeal carcinoma (NPC) patients without distant metastasis.
- Trial name
- NCT06282497
- Testing
- Optimised neck CTV, standard neck CTV
- Where
- China
- Volunteers
- 524 people
- Sponsor
- Zhongshan People's Hospital, Guangdong, China
Head and Neck Cancer
Cisplatin Plus Epinephrine in Treating Patients With Recurrent or Refractory Head and Neck Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells.
- Trial name
- NCT00002659
- Testing
- cisplatin-e therapeutic implant
- Where
- 28 sites in United States, Canada
- Volunteers
- 120 people
- Sponsor
- Matrix Pharmaceutical
Nasopharyngeal Cancinoma (NPC), Nasopharangeal Cancer
Phase III Trial of EBV-DNA-Guided Adaptive Immunotherapy for Advanced Nasopharyngeal Carcinoma
This trial evaluated the efficacy of two adjuvant regimens following identical induction and concurrent chemoradiotherapy (IC+CCRT) in locoregionally advanced nasopharyngeal carcinoma (LANPC) patients with persistent EBV DNA…
- Trial name
- NCT07238569
- Testing
- Adebrelimab (PD-L1 inhibitor), Cisplatin (100mg/m2), Intensity-modulated radiotherapy
- Volunteers
- 516 people
- Sponsor
- Sun Yat-sen University
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.